title: KW-2170 (Kyowa Hakko Kogyo).
abstract: The pyrazoloacridone, KW-2170, an alkylating agent and topoisomerase II inhibitor, is being developed by Kyowa Hakko Kogyo as a potential treatment for cancer [273964], [409111], [422561]. By December 2001, KW-2170 had entered phase II trials in the US, following approval for the trial from the FDA, which was received in November 2001. At this time, the company planned to extend the phase II trials to Australia, Singapore, Taiwan and Costa Rica using data from US phase I trials. Accelerated Japanese trials were also planned, and an NDA was anticipated for 2006, with non-small-cell lung cancer, prostate cancer, colorectal cancer, ovarian cancer and breast cancer as the targets [434794], [444539]. By August 2002, Japanese phase I trials had been completed [460177].
authors.affiliation: UNM Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque, NM 87131, USA. cverschraegen@salud.unm.edu
authors.forename: Claire F
authors.initials: CF
authors.lastname: Verschraegen